{"id":"W4399509789","doi":"10.1093/ndt/gfae132","title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","year":2024,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"National Institutes of Health; Akebia Therapeutics; Vifor Pharma; Astellas Pharma; Impulse Dynamics; Novo Nordisk; ReCor Medical; National Medical Research Council; Ingham Institute for Applied Medical Research; Cytokinetics; Genesis Pharma; Vertex Pharmaceuticals; Boston Scientific Corporation; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; Sanofi; American Society of Nephrology; Medical Research Council; Bayer; Victor Chang Cardiac Research Institute; Amgen","keywords":"Medicine; Kidney disease; Internal medicine; Renal function; Randomized controlled trial; Diabetes mellitus; Tolerability; Placebo; Type 2 diabetes; Adverse effect; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004793493,0.002119539,0.004108605,0.0004847354,0.0005589654,0.001732511,0.0008893603,0.00206963,0.01611874],"category_scores_gemma":[0.006068185,0.0007384475,0.002741338,0.0006374898,0.0008779421,0.001701341,0.0007502064,0.003053701,0.001291636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007765664,"about_ca_system_score_gemma":0.001212331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009916609,"about_ca_topic_score_gemma":0.002045498,"domain_scores_codex":[0.9969714,0.001709463,0.0002571516,0.000539624,0.0002322938,0.0002899743],"domain_scores_gemma":[0.9980286,0.0005796372,0.0005990787,0.0001667684,0.0002031618,0.0004227101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9903761,0.001039736,0.001062252,0.0006302556,0.001630371,0.00002278431,0.00002190862,0.0002194177,0.0002680206,0.0002201179,0.001179993,0.003329095],"study_design_scores_gemma":[0.9858977,0.009463497,0.001839277,0.00007188258,0.001131871,0.000017002,0.00001514281,0.000270085,0.00006866355,0.0003611154,0.0008490732,0.00001465603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8601699,0.01764879,0.004060189,0.004488127,0.002803514,0.07365946,0.01763499,0.0003258346,0.01920909],"genre_scores_gemma":[0.8745949,0.004145886,0.005384991,0.00474513,0.00115463,0.09138237,0.00836279,0.000066385,0.01016285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01611874,"threshold_uncertainty_score":0.05392253,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007129561595460208,"score_gpt":0.2410019234860091,"score_spread":0.2338723618905489,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}